Care of patients with non-small-cell lung cancer stage III - The Central European real-world experience

Milada Zemanova (Coresponding Author), Robert Pirker, Lubos Petruzelka, Zuzana Zbozínkova, Dragana Jovanovic, Mirjana Rajer, Krisztina Bogos, Gunta Purkalne, Vesna Ceriman, Subhash Chaudhary, Igor Richter, Jirí Kufa, Lenka Jakubikova, Marius Zemaitis, Marketa Cernovska, Leona Koubkova, Zdenka Vilasova, Karin Dieckmann, Attila Farkas, Jelena SpasicKaterina Fröhlich, Andreas Tiefenbacher, Virag Hollosi, Juraj Kultan, Iveta Kolarová, Jiri Votruba

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.

Original languageEnglish
Pages (from-to)209-220
Number of pages12
JournalRadiology and Oncology
Issue number2
Publication statusPublished - 28 May 2020
Externally publishedYes


  • diagnostic procedures
  • multimodality treatment
  • non-small-cell lung cancer
  • stage III

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database


Dive into the research topics of 'Care of patients with non-small-cell lung cancer stage III - The Central European real-world experience'. Together they form a unique fingerprint.

Cite this